HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

Benzinga Newsdesk www.benzinga.com Positive 81.6%

Neg 0% Neu 0% Pos 81.6%

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.